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Abstract: Autologous iliac crest bone graft is the preferred option for spinal fusion, but the morbidity associated with 
bone harvest and the need for graft augmentation in more demanding cases necessitates combining local bone with bone 
substitutes. The purpose of this study was to document the clinical effectiveness and safety of a novel hybrid biosynthetic 
scaffold material consisting of poly(D,L-lactide-co-glycolide) (PLGA, 75:25) combined by lyophilization with 
unmodified high molecular weight hyaluronic acid (10-12% wt:wt) as an extender for a broad range of spinal fusion 
procedures. We retrospectively evaluated all patients undergoing single- and multi-level posterior lumbar interbody fusion 
at an academic medical center over a 3-year period. A total of 108 patients underwent 109 procedures (245 individual 
vertebral levels). Patient-related outcomes included pain measured on a Visual Analog Scale. Radiographic outcomes 
were assessed at 6 weeks, 3-6 months, and 1 year postoperatively. Radiographic fusion or progression of fusion was 
documented in 221 of 236 index levels (93.6%) at a mean (±SD) time to fusion of 10.2+4.1 months. Single and multi-
level fusions were not associated with significantly different success rates. Mean pain scores (+SD) for all patients 
improved from 6.8+2.5 at baseline to 3.6+2.9 at approximately 12 months. Improvements in VAS were greatest in 
patients undergoing one- or two-level fusion, with patients undergoing multi-level fusion demonstrating lesser but still 
statistically significant improvements. Overall, stable fusion was observed in 64.8% of vertebral levels; partial fusion was 
demonstrated in 28.8% of vertebral levels. Only 15 of 236 levels (6.4%) were non-fused at final follow-up. 
Keywords: Bone extender, hyaluronic acid, intervertebral level, local bone autograft, lumbar fusion. 
INTRODUCTION 
 With increasing understanding of the biological and 
biomechanical basis of bone fusion, the quest for better and 
more efficient bone fusion technologies in spinal surgery 
continues. While autologous iliac crest bone is recognized as 
the most successful grafting material due to its osteoconduc-
tive, osteogenic and osteoinductive properties [1, 2], compli-
cation rates of this invasive procedure remain high [3-5], 
with protracted postoperative pain at the donor site being the 
most commonly reported complication [6]. In an attempt to 
limit such complications by either reducing or eliminating 
iliac crest autograft harvest, demineralized bone matrix 
(DBM) and synthetic osteoconductive bone graft extenders 
(BGEs) are often used in spinal fusion procedures as an 
adjunct to patient-derived autograft [7-11]. Similarly, local 
bone may be used in lieu of iliac crest grafts, although 
current evidence suggests that while local bone is equally 
effective as iliac crest bone in single-level fusion [6, 12], it 
has been associated with significantly lower fusion rates 
when utilized in multi-level fusion due to volume limitations 
[1]. 
 A number of bone graft substitutes are available, the 
most common of which are ceramic- or calcium-phosphate- 
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based synthetic materials. While these products provide a 
suitable scaffolding upon which to build new bone, they are 
inherently unable to stimulate bone growth without the 
patient’s own bone or marrow to augment the process. 
Alternate options such as tricalcium phosphate, calcium 
sulfate and hydroxyapatite, while possessing osteoconduc-
tive properties, are associated with equivocal results 
regarding fusion rates [13]. To address the shortcomings of 
the currently available technology, a fully-resorbable hybrid 
biosynthetic autograft extender for use in spinal fusion was 
developed (InQu®, ISTO Technologies, Inc., St. Louis, MO). 
This extender, which has been commercially available since 
2008, contains no ceramic component and no animal-derived 
protein. Instead, it consists of poly(D,L-lactide-co-glycolide) 
(PLGA, 75:25) combined by lyophilization with unmodified 
high molecular weight hyaluronic acid (10-12% wt:wt) to 
create a hybrid interwoven scaffold. The PLGA component 
provides compressive resistance to maximize the product's 
bulking properties. The rate of polymer resorption (3-6 
months) is consistent with the rate of bone remodeling at the 
site of implantation, and this scaffolding support has been 
shown to direct new bone growth via endochondral 
ossification [14, 15], in contrast to ceramic-based materials, 
which function through creeping substitution [16]. 
 In order to evaluate the safety and clinical effectiveness 
of the new hybrid interwoven biosynthetic bone extender, we 
retrospectively analyzed a consecutive series of posterior 
lumbar interbody fusion (PLIF) procedures with supplemental 
instrumentation. 
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METHODS 
 All patients who underwent elective PLIF procedures at a 
single academic medical center between March 2008 and 
March 2011 utilizing the new hybrid interwoven biosynthetic 
bone extender were included in this analysis. All patients 
signed an institutional consent form that explained all 
treatment modalities offered to these patients. No 
Institutional Review Board (IRB) review was sought as all 
procedures were performed under our center’s standard of 
care and did not involve any additional research-oriented 
procedure or products. 
 One author (MKC) performed a retrospective chart 
review of eligible patients. The goal of the review and data 
collection was to document the rate of fusion progression at 
approximately 18 months of follow-up together with the rate 
of complications and changes in pain scores and other 
patient-reported outcomes. 
Surgical Procedure 
 Surgery was performed using standard surgical 
techniques of decompression and fusion. In all cases, local 
bone was harvested during the decompression procedure 
using an irrigated high speed burr and mucous trap. The 
harvested bone was combined with concentrated bone 
marrow aspirate (cBMA) obtained from the posterior iliac 
crest. In the vast majority of cases (95/109, 87%), the local 
bone/cBMA mixture was first extended with a cancellous 
crunch allograft (5-10 cc) before addition of the hybrid 
interwoven biosynthetic bone extender (5-10 cc). DBM was 
additionally used in 55 cases (50%). The formulation of 
InQu (granules or paste mix) was selected for each 
individual patient based on the amount of bulk necessary to 
fill the bone void. Nearly all cases (95/109, 87%) used 10 cc 
of paste mix, while 10 cases (8.7%) utilized granules. The 
formulation used was not recorded in 4 cases. 
 In all patients, the bone grafting material was placed into 
the interbody space and the posterolateral gutters as per 
standard instrumentation procedures. Disc spaces were 
augmented with 15 cc of bone graft material prior to 
interbody placement. Interbody cages were used in all cases, 
with the disc space filled to its entirety. Constructs varied 
from 1 to 7 intervertebral levels with all cases supported by 
standard instrumentation (standard rods, screws and when 
necessary, crosslinks). 
Outcomes 
 Patient Reported Outcomes – Pain severity were reported 
subjectively using a visual analog scale (VAS) ranging from 
0 (no pain) to 10 (worst pain imaginable). The minimum 
improvement in VAS required to indicate a minimally 
clinically important difference (MCID) ranges from 1.3 [17] 
to 3.0 [18], depending on study and field. For the purposes of 
this analysis, we set our MCID at an improvement of 2.0 
points on the 10-point VAS, which is consistent with similar 
studies from this field [19-22]. 
 Radiographic Outcomes – Radiographs were obtained at 
baseline and post-procedure at 6 weeks, 3-6 months, and 12 
months; computed tomography (CT) scans were collected 3-
6 months and 12 months post-procedure. Independent board-
certified neuroradiologists reviewed both static and dynamic 
radiographs and CT scans to determine fusion status. In all 
cases, fusion status was defined by the presence of 
continuous bridging bone between the endplates. Delayed or 
non-union was characterized by the presence of visualized 
intervertebral clefts or a vacuum-phenomenon [23]. Fusion 
was rated as either 0 (non-fusion), 1 (incomplete or 
progression of fusion) or 2 (stable/solid fusion), with 
procedures rated either “1” or “2” on this scale deemed to 
have been successful. 
 Outcomes for safety were evaluated by recording the 
nature and frequency of all adverse events that required 
medical attention or reoperation. 
Statistical Analysis 
 Alpha was set a priori at 0.05 for all statistical 
comparisons. Means were compared using Student’s t-tests 
assuming unequal variances and/or single-factor ANOVA. 
All mean values are presented as mean (+SD). VAS and 
VAS responder rates are presented as mean value (+SD).  
RESULTS 
 One hundred nine (109) procedures were performed on 
108 patients involving 245 individual vertebral levels. 
Patient background characteristics and pre-surgical 
diagnoses are summarized in Table 1. The mean age was 
59.4 (+12.4 yrs, range 28-85 yrs); 56% of patients were 
female. Only 39 patients (36%) reported working prior to the 
surgery. Mean body mass index (BMI) was 30.2 (+5.7). 
Mean clinical follow-up was 19.2 (+11.7) months, while 
 
Table 1. Patient characteristics and diagnosis. 
 
 All Patients (n=108) 
Mean age at time of first surgery 59.4 (12.4) (range: 28- 85) 
Gender  
Male 47 (44%) 
Female 61 (56%) 
Mean BMI at time of surgery 30.2 (5.7) 
Diagnosis  
Degenerative spinal stenosis 58 (53%) 
Degenerative spondylolisthesis 60 (55%) 
Non-specific low back pain 18 (17%) 
Degenerative scoliosis 6 (6%) 
Instability 3 (3%) 
Radiculopathy 4 (4%) 
Degenerative disc disease 3 (3%) 
Post laminectomy syndrome 1 (1%) 
 
mean radiological follow-up was 17.7 (+10.4) months. Three 
patients (2.8%), accounting for a total of 9 fusion levels, did 
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not return for full follow-up. Of the initial 245 levels fused, 
complete data are available for 236 levels. 
 PLIF procedures at all 245 levels were instrumented. A 
detailed summary of the distribution of index levels is 
provided in Table 2; procedural details are summarized in 
Table 3. Spinal fusion was performed at a single level in 32 
patients (29.4%), at two levels in 37 patients (33.9%) and at 
three or more levels in 40 patients (36.7%). 
Table 2. Details of spine fusion procedure. 
 
 All Procedures  
(N=109) 
Fusion type  
Posterior lumbar interbody fusion (PLIF) 109 (100%) 
Number of operated intervertebral levels  
1 32 (29.4%) 
2 37 (33.9%) 
3 30 (27.5%) 
4 6 (5.5%) 
5 1 (0.9%) 
6 1 (0.9%) 
7 2 (1.8%) 
Source of bone  
Local autograft (bone dust) 109 (100%) 
Autologous bone marrow cBMA  109 (100%) 
Extenders  
Cancellous allograft extender 95 (87%) 
Demineralized bone matrix 55 (50%) 
Other (injectable protein polymer formulation *) 1 (1%) 
InQu formulation used  
Paste  95 (87%) 
Granules 10 (9%) 
Not recorded 4 (4%) 
*NuCoreTM Injectable Disc Nucleus, Protein Polymer Technologies, Inc., San Diego, 
CA. 
Abbreviations: cBMA: concentrated bone marrow aspirate. 
Clinical Outcomes, Time to Fusion and Fusion Rate 
 Data at final follow-up were available for 236 of 245 
individual levels in 105 patients. A total of 221 of 236 
vertebral levels (93.6%) fulfilled the success criteria for 
fusion at final follow-up by demonstrating partial or comp-
lete fusion (see Table 4). Partial fusion was demonstrated at 
68 of 236 fusion levels (28.8%) at final follow-up while 153 
of 236 levels (64.8%) demonstrated complete fusion. Only 
15 of 236 levels (6.4%) showed no evidence of fusion at 
final follow-up. The mean time to fusion for the entire group 
was 10.2 months (+4.1). An example of solid fusion is 
demonstrated in Fig. (1). 
Single-Level Fusion 
 Spinal fusion was performed at a single level in 32 
patients (29.4%). The majority of these procedures (21) were 
performed at the L4/L5 level, with 4 procedures performed 
at the L3/L4 level and 7 performed at the L5/S1 level. The 
mean age of this subgroup was 58.1 yrs (+14.4) with a mean 
BMI of 28.8 (+5.6). Mean blood loss in this subgroup was 
127 mL (+47) while mean LOS was 3.7 days (+1.7). 
 Spinal fusion was rated as successful (complete or partial 
fusion) in a total of 30 (93.8%) single-level patients. Non-
fusion was observed in only 2 (6.3%) patients. Of those 
patients deemed successfully fused, progression toward or 
partial fusion was observed in 8 (25%), while 22 patients 
(68.8%) demonstrated stable or complete fusion. The mean 
time to fusion in this group was 10.7 months (+ 3.9). 
 The use of DBM was associated with a higher overall 
success rate as compared to cases where DBM was not 
utilized. In cases where DBM was utilized (n=14), 100% of 
patients were found to fulfil the success criteria for fusion, 
21% (3/14) of which demonstrated partial fusion and 79% 
(11/14) demonstrated complete fusion. In contrast, in cases 
where DBM was not utilized (n=18), 87% of patients 
demonstrated successful fusion, with 28% (5/18) showing 
partial fusion and 61% (11/18) showing complete fusion. No 
patients in the group using DBM showed non-fusion at the 
final follow-up whereas 2 (13%) of those who did not utilize 
DBM were considered non-fused (see Table 5). 
Two-Level Fusion 
 A total of 37 patients underwent spinal fusion at two 
levels. The majority of these procedures (26) were performed 
between L4 and S1. Ten procedures were performed between 
L3 and L5, with one procedure occurring between L2 and 
L4. The mean age of this subgroup was 56.0 yrs (+ 11.8). 
Mean blood loss was 230 mL (+102); mean LOS was 4.2 
days (+1.5) and mean BMI was 29.5 (+4.6). 
Table 3. Demographic characteristics sub-grouped based on number of index levels fused. 
 
 Single-Level 
 (n=32 pts, 32 levels) 
Two-Level 
 (n=37 pts, 74 levels) 
Multi-Level  
(n=40 pts, 139 levels) 
p-Value  
(ANOVA) 
Age, mean (SD) 58.1 (14.4) 56.0 (11.8) 63.7 (10.1) 0.066 
BMI, mean (SD) 28.8 (5.6) 29.5 (4.6) 39.1 (6.4) 0.041 
Blood loss (mL), mean (SD) 127 (47) 230 (102) 426 (245) <0.00012 
Length of stay (days), mean (SD) 3.7 (1.7) 4.2 (1.5) 4.9 (2.6) 0.051 
1Single level vs multi-level comparison: p=0.027. All other paired comparisons: p>0.05. 
2p<0.0001 for ANOVA and all paired t-tests. 
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 Successful fusion was observed in 31 of 36 (86.1%) of 
patients (one patient in this group was lost to follow-up). Six 
patients (16.7%) were deemed to have progression toward or 
partial fusion while 25 (69.4%) were classified as stable or 
complete fusion. Non-fusion was observed in 5 (13.9%) 
patients. The mean time to fusion was 9.5 months (+3.9). 
 The use of DBM in two-level fusions was not associated 
with better success rates. Patients where DBM was utilized 
 
Fig. (1). Sagittal (A, C) and coronal (B, D) CT images at 9 months (A, B) and 16 months (C, D) post-op in a 54-year-old male who 
underwent 2-level posterior lumbar interbody fusion at L4-S1 (yellow arrows). The patient complained of low back pain and left buttock pain 
after failed previous fusion at L5-S1. Nine-month imaging demonstrates progression to fusion (A, B), with complete fusion realized by 16-
month imaging at the time fusion was extended to include L2-L4 (C, D). Low back pain and radiculopathy resolved following re-operation. 
Running Head: InQu autograft extender in PLIF 
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Figure 1 
Figure 1. Sagittal (A, C) and coronal (B, D) CT images at 9 months (A, B) and 16 months (C, D) post-op in a 
54-year-old male who underwent 2-level posterior lumbar interbody fusion at L4-S1 (yellow arrows). The 
patient complained of low back pain and left buttock pain after failed previous fusion at L5-S1. Nine-month 
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showed an 86% overall success rate (4/22 (18%) partial 
fusion and 15/22 (68%) complete fusion), while cases not 
using DBM showed an 85% overall success rate (2/14 (14%) 
partial fusion and 10/14 (71%) complete fusion). 
Multi-Level Fusion 
 Fusion at greater than 2 levels occurred in 40 patients 
(see Table 2). The majority of patients were fused at 3 levels 
(30/40, 75%), with 10 additional patients undergoing fusion 
at greater than 3 levels. The mean age of this group was 63.7 
yrs (+10.1). Mean blood loss was 426 mL (+245); mean LOS 
was 4.9 days (+2.6); and mean BMI was 31.9 (+6.4). 
 Two patients in this group were lost to follow-up and had 
no final fusion status. In the remaining 38 patients, fusion 
was deemed successful in 37 (97.4%). Only 1 patient (2.6%) 
was categorized as not fused. Of the successful fusion 
patients, 15 (39.5%) were observed to have progression 
toward or partial fusion, while 22 (57.9%) were categorized 
as stable or complete fusion. The mean time to fusion was 
10.4 months (+4.4). 
Table 4. Final follow-up observed fusion rates based on number of levels fused. 
 
 Full Follow-Up Procedures (n=105 Patients, 236 Levels) 
Time to last follow-up CT scan  
Mean (SD), months 17.7 (10.4) 
Median (Min, Max), months 17.1 (1, 45.5) 
Time to stable or progression of fusion  
Mean (SD), months 10.2 (4.1) 
Median (Min, Max), months 10 (1, 24) 
All cases, n (%)  
 Stable or progression 221/236 (93.6) 
Stable/good 153/236 (64.8) 
Incomplete/progression 68/236 (28.8) 
 Non-fusion 15/236 (6.4) 
Stable or progression rate by number of levels involved, n (%)  
1-level cases (n=32), overall 30/32 (93.8) 
Partial/incomplete fusion 8/32 (25) 
Complete fusion 22/32 (68.8) 
2-level cases (n=36), overall 62/72 (86.1) 
Partial/incomplete fusion 12/72 (16.1) 
Complete fusion 50/72 (69.4) 
3-level cases (n=30), overall 84/87 (96.6) 
Partial/incomplete fusion 42/87 (48.3) 
Complete fusion 42/87 (48.3) 
4-level cases (n=5), overall 20/20 (100) 
Partial/incomplete fusion 0/20 (0) 
Complete fusion 20/20 (100) 
5-level cases (n=1), overall 5/5 (100) 
Partial/incomplete fusion 0/5 (0) 
Complete fusion 5/5 (100) 
6-level cases (n=1), overall 6/6 (100) 
Partial/incomplete fusion 6/6 (100) 
Complete fusion 0/6 (0) 
7-level cases (n=2), overall 14/14 (100) 
Partial/incomplete fusion 0/7 (0) 
Complete fusion 14/14 (100) 
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 Fusion at three levels was performed in 29 patients, of 
whom 96.6% (28) had partial or complete fusion. Four-level 
fusion occurred in 6 patients, 1 of whom was lost to follow-
up. Of the remaining 5 patients, all demonstrated partial or 
complete fusion at the final follow-up. Five- and six-level 
fusion was performed in 1 patient each while 2 patients 
underwent seven-level fusion. At the final follow-up, the 
patients undergoing 5- and 7-level fusion demonstrated 
complete fusion while the patient who underwent 6-level 
fusion demonstrated partial fusion. 
 The use of DBM had no effect on fusion rate in multi-
level fusion cases. The overall success rate for fusion in the 
nine cases where greater than two levels were fused was 
100% in all but one case, which demonstrated a 94% success 
rate with no DBM at 3-levels. 
Patient-Reported Pain 
 Mean pain scores (+SD), as measured by VAS, improved 
significantly both immediately post-surgery and at 12-month 
follow-up. Overall, there was a statistically significant 
decrease in VAS both immediately post-operatively (6.8+2.5 
vs 3.1+2.9, p<0.001) and 12-months post-operatively 
(6.8+2.5 vs 3.6+2.9, p<0.001), when compared with baseline 
VAS. Immediately post-surgery, 70.0% of all patients had 
realized a MCID in VAS scores. This improvement was 
consistent across all patients, regardless of the number of 
operative levels. Detailed patient responder rates are 
summarized in Table 6. 
Adverse Events and Re-Interventions 
 No complications arising from the specific use of the 
hybrid interwoven biosynthetic bone extender were recorded 
in any of the 109 cases. Furthermore, no seromas and no 
heterotopic bone formation were observed. Re-operations 
performed during the follow-up period are summarized in 
Table 7. Procedural complications requiring medical 
attention and/or return to surgery included one patient seen 
for superficial infection at 3 months who was treated and 
released. Two additional patients developed hematoma and 
were treated immediately without neurologic sequelae. No 
cases of subsidence were reported. In addition, over the 
course of the follow-up period, 12 re-interventions were 
performed for hardware removal or replacement, and 9 
patients required an extension of their surgical construct due 
to progressive degeneration of the spine. 
 Of the 39 patients who reported to be working prior to 
surgery, 56% (22/39) successfully returned to work. 
DISCUSSION 
 The objective of this retrospective review was to investigate 
the safety and clinical effectiveness of InQu, a novel 
biosynthetic osteoconductive scaffold used as a local autograft 
extender in PLIF with supplemental instrumentation. This 
retrospective case series with radiologic assessment of fusion 
comprised 109 cases in 108 subjects at 245 individual lumbar 
spine levels. Local bone harvested during the decompression 
Table 6. Pain severity responder rates. 
 
 Pre-op VAS,  
Mean (SD) 
Post-op VAS,  
Mean (SD)1 
12-Month Post-Op 
 VAS, Mean (SD)1 
Patients Achieving  
MCID Immediately Post-Op, n (%) 
Patients Achieving  
MCID 12-Months Post-Op, n (%) 
All patients 6.8 (2.5) 3.1 (3.0) 3.6 (2.9) 63/90 (70.0) 36/54 (66.7) 
Single-level 6.6 (2.8) 2.8 (3.1) 2.7 (3.1) 18/26 (69.2) 10/15 (66.7) 
Two-level 6.1 (2.6) 2.6 (3.0) 3.2 (2.5) 18/26 (69.2) 12/18 (66.7) 
Multi-level 7.6 (1.8) 3.8 (2.9) 4.8 (3.0) 23/33 (69.7) 12/18 (66.7) 
1p<0.001 for all pre-op vs post-op comparisons. 
Pre-op: pre-operative. 
Post-op: post-operative. 
VAS: visual analog scale. 
MCID: minimally clinically important difference. 
Table 5. Fusion success rates, based on fused level, for cases utilizing DBM and those not utilizing DBM. 
 
 
DBM (122 Levels) Non-DBM (114 Levels) 
Overall Success1 Rate, n (%) Detailed Fusion Rates, n (%) Overall Success Rate, n (%) Detailed Fusion Rates, n (%) 
Single-level fusion 14/14 (100) 
No fusion: 0/14 (0) 
Partial: 3/14 (21) 
Complete: 11/14 (79) 
16/18 (87) 
No fusion: 2/18 (13) 
Partial: 5/18 (27.8) 
Complete: 11/18 (61) 
Two-level fusion 38/44 (86.4) 
No fusion: 6/44 (13.6) 
Partial: 8/44 (18.2) 
Complete: 30/44 (68.2) 
24/28 (85.7) 
No fusion: 4/28 (14.3) 
Partial: 4/28 (14.3) 
Complete: 20/28 (71.4) 
Multi-level fusion 64/64 (100) 
No fusion: 0/64 (0) 
Partial: 27/64 (42.2) 
Complete: 37/64 (57.8) 
65/68 (95.6) 
No fusion: 3/68 (4.4) 
Partial: 21/68 (30.9) 
Complete: 44/68 (64.7) 
1Overall success defined as patient achieving partial or complete fusion at final follow-up. 
DBM: demineralized bone matrix. 
224    The Open Orthopaedics Journal, 2015, Volume 9 Chedid et al. 
procedure was combined with the hybrid interwoven 
biosynthetic bone extender and this mixture was hydrated with 
concentrated bone marrow harvested from the posterior iliac 
crest. Posterolateral fusion was then achieved utilizing the same 
grafting materials placed within the interbody (IB) device and 
into the disc space. 
Table 7. Post-procedural re-operations. 
 
Type of Events  Number of Events 
Hardware removal/replacement 12 
Extension of construct to adjacent levels 9 
Laminectomy, foraminotomy and/or decompression 3 
Hematoma 2 
Adjacent level decompression 2 
Failure 1 
Infection 1 
Augmented fusion 1 
 
 The new hybrid interwoven biosynthetic bone extender 
appears to safely support bone formation when applied to the 
axial skeleton. A total of 64.8% of the 245 individual vertebral 
levels demonstrated complete and stable fusion at final follow-
up, with an additional 28.8% of vertebral levels demonstrating 
progression toward fusion. Thus, a total of 221 of 236 vertebral 
levels (93.6%) fulfilled the success criteria for fusion, while 
only 15 of 236 levels (6.4%) showed lack of fusion at final 
follow-up. The mean time to fusion was an acceptable 10.2 
months. No safety concerns were raised with use of the product, 
including the lack of heterotopic ossification. There were no 
reported cases of implant failure, deep wound infection or 
seroma formation post-surgery. No loosening or failure of the 
hardware was noted. 
 While technically more difficult and typically associated 
with greater complication rates than anterior lumbar interbody 
fusion (ALIF) and transforaminal lumbar interbody fusion 
(TLIF) procedures [24-26], the PLIF procedure – first pioneered 
in the 1950s [27-29] – is associated with high fusion rates, 
which has resulted in its remaining a staple of lumbar fusion. 
The current case series demonstrated satisfactory fusion rates in 
patients necessitating mechanical stabilization of single, double 
and multiple levels without neurological complication. Previous 
reports have suggested that the use of local bone in cases of 
multiple level fusion is associated with poor fusion outcomes, 
necessitating the use of iliac bone grafts [1, 30]. The current 
study, however, demonstrates successful fusion in 37 of 38 
patients undergoing fusion at 3 or more levels (representing 129 
of 132 levels). This indicates that the use of local bone in multi-
level fusion is feasible when combined with an extender such as 
InQu. These data complement previous studies that have shown 
similar levels of fusion success when utilizing local bone. 
Coutour et al. [31] utilized the HYDROSORB bio-absorbable 
implant packed with locally harvested autograft and segmental 
internal fixation in a group of 27 patients undergoing PLIF and 
showed comparable efficacy, with 95.5% (42 of 44) of vertebral  
 
levels demonstrating successful fusion. They noted, however, 
that the rate of fusion was inversely proportional to the number 
of levels being fused, whereas we observed a nearly equivalent 
rate of fusion in single-, double- and multi-level fusion cases. 
 The fusion rates demonstrated in this report are comparable 
to those observed with the use of other bone graft extenders and 
fusion performed without BGE. Fusion rates above 85% at 2 to 
3 years post-procedure have been demonstrated for both local 
and iliac crest bone grafts [12, 32]. Synthetic BGEs have been 
associated with similar rates of fusion success, with one recent 
systematic review [7] reporting an 86.4% fusion rate when 
ceramic materials were utilized as the BGE, while another 
systematic review [13] found pooled fusion rates ranged from 
75% with calcium sulphate to 98.2% with a combination of 
hydroxyapatite and tricalcium phosphate. The current study 
included supplemental posterolateral fusion for which greater 
quantities of bone graft are required. Despite the finite volume 
of autograft that could be harvested locally, concentrated bone 
marrow aspirate combined with cancellous allograft and 
biosynthetic extender appeared to provided adequate osteogenic 
and osteoconductive support of new bone growth. 
 In conclusion, the clinical experience of a single clinical site 
in a 109 case series of subjects requiring PLIF procedures using 
a fully-resorbable osteoconductive scaffold made of PLGA with 
integrated hyaluronic acid demonstrates that this biosynthetic 
bone graft extender provides good to excellent radiographic 
outcomes in approximately 94% of patients. Most importantly, 
this study demonstrates that the use of the InQu extender allows 
for the use of local bone and resulted in a 97.7% fusion rate in 
38 patients undergoing multiple level (>3) fusion. Additional 
prospective studies evaluating its clinical success for one- and 
two-level transforaminal lumbar interbody fusion procedures 
will add to these clinical findings. 
ABBREVIATIONS 
ALIF = Anterior lumbar interbody fusion 
ANOVA = Analysis of variance 
BGE = Bone graft extender 
BMI = Body mass index 
cBMA = Concentrated bone marrow aspirate 
CT = Computed tomography 
DBM = Demineralized bone matrix 
IB = Interbody 
IRB = Institutional Review Board 
LOS = Length of stay 
MCID = Minimal clinically important difference 
PLGA = Poly(D,L-lactide-co-glycolide) 
PLIF = Posterior lumbar interbody fusion 
SD = Standard deviation 
TLIF = Transforaminal lumbar interbody fusion 
VAS = Visual analog scale 
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